An Army private, who recently was sentenced by a military court to 12 ½ years in prison for the murder of an Afghan detainee, walked into a cell at a U.S. outpost in Afghanistan and shot the sleeping prisoner, according to prosecutors. Army doctors later found that the soldier was suffering from schizophrenia and PTSD.
Cases such as these make accurate schizophrenia screening and treatment critical for the military, but the process is complicated by a simple fact: The age of initial onset of schizophrenia symptoms coincides closely with the age at which many enter the military; schizophrenia usually appears between ages 16 to 25 with an average onset of age 18 for men and slightly older for women.
Schizophrenia is a chronic, severe, and disabling brain disorder that appears to be caused by some combination of genetic makeup and brain chemistry, according to the NIH.
While the consequences of enlisting a schizophrenic servicemember can be significant, screening also is difficult because of the relative rarity of the disease and because sufferers are likely to try to hide it, if they can.
“You have to realize that while schizophrenia is prevalent, there has been found to be a lifetime occurrence of between .3% and .7% in various studies in the population,” Navy Capt. Paul S. Hammer, director of the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, told U.S. Medicine.
“You need to remember that the incidence of psychotic disorders is less than 100 a year in the entire military, so it’s not all that common,” Hammer says. “When it does occur, it’s obvious enough that people know what to do and they are able to get the individual appropriately referred.”
What the Military Does
Mental health screening questions are included on health-related questionnaires, but Hammer said they tend to be general and are more likely to address concerns for depression.
Routine mental health screenings also occur when servicemembers present for primary care. For example, Hammer says, the physician might wish to screen for depression,i.e., “Do you feel sad or down?”. “For large troop concentrations they may also ask questions related to PTSD,” he adds.
When patients say they are feeling depressed or having difficulty sleeping, more questions are asked to gauge the seriousness of the problem, according to Hammer.
“If they say they’re sad, you would ask them to tell you about it; whether there are is anything going on in their lives, issues they’re having difficulty dealing with, and so on, although these are more targeted towards depression,” he says.
Specific behaviors that could indicate the possible presence of schizophrenia, Hammer says, might include paranoia or hallucinations, adding that it’s rare for such an individual to come forward and admit they have a problem and, “Usually there is an attempt to hide it and be in denial.”
Clinicians should take a close look at individuals who are attempting to isolate themselves, according to Hammer, who explains that, with symptoms of schizophrenia, “They might behave in an odd or bizarre manner; personal or social interactions might be rather odd – or they become overly suspicious.”Difficulties in Detecting Schizophrenia Can Have Serious Consequences in Military Setting Cont.
Be Aware of Vulnerabilities
Stress and behaviors during deployment sometimes can set off the disease in servicemembers who demonstrated no obvious schizophrenia symptoms at enlistment, adds Cheryl Corcoran, MD, assistant professor of clinical psychiatry at Columbia University Medical Center and director of the Center of Prevention and Evaluation at the New York State Psychiatric Institute,
“I think there’s a lot of evidence to suggest that stress as well as exposure to different drugs like cannabis or methamphetamine in people who have a pre-existing vulnerability to psychosis might trigger onset or exacerbate existing attenuated symptoms,” says Corcoran. Cortisol is released throughout the body during the fight-or-flight response and, she points out, “And dopamine release is increased in the brain, which in vulnerable individuals can lead to psychotic symptoms.”
Earlier this year, a metanalysis of more than 80 studies found that the mean age at onset of psychotic disorders, including schizophrenia, was more than 2.5 years earlier for marijuana users compared with nonusers.1
Corcoran lists a number of ways to help identify which individuals might be vulnerable to developing schizophrenia.
One, for example, is a family history of psychosis, especially involving a first-degree family member and combined with drug use.
“There are certain genes related to vulnerability to having psychotic symptoms when exposed to stress or using marijuana,” Corcoran explains. For example, she notes, the enzyme Catechyl-O-Methyl-Transferase breaks down dopamine – which is involved in psychosis, but none of these are “black or white” situations, meaning the risk factor alone is not enough to predict psychosis.
More indicative of vulnerability, Corcoran continues, are clinical symptoms that are sub-threshold – i.e., a diagnosis has not yet been reached. “Someone might have schizotypal features such as being odd, having magical thinking, or social awkwardness; that represents vulnerability,” she says.
A key indication would be unusual thought content that evolves over time into a delusion, says Corcoran, adding, “This also includes suspiciousness; that’s a real risk for psychosis.” In addition, she says military health providers should look for “perceptual disturbance, like hearing voices.” Before actually hearing voices, she explains, the individual may hear knocking, or their name being called in the wind. “These are subtle things, but you can start to see patterns.”
Other than looking for those symptoms, “there is not a really good screen,” Corcoran says, adding “What you might want to do is de-stigmatize these kinds of symptoms so the few people who do have them would seek help.”
Questionnaire May Be Beneficial
That may be changing based on research published this summer in the journal Schizophrenia Research on the use of a prodormal self-report questionnaire to help detect early stages of schizophrenia, before full-blown psychosis develops.2
In its full form, the 92-item questionnaire, which takes approximately 20 minutes to complete, focuses on four major areas:
- Milder forms of positive symptoms (i.e., “unusual thinking” or “perceptual abnormalities.”)
- Negative symptoms (which can include limited facial expressions of emotions.)
- Disorganized symptoms (i.e., odd, difficult to understand behavior.)
- General symptoms (which can include depression and the ability to perform daily activities of living.
Rachel Loewy, PhD, of the Department of Psychiatry at UCSF, and colleagues used a brief version of the questionnaire with adolescents and young adults. “Endorsement of three or more positive symptoms on the PQ-B (Podromal Questionnaire Brief version) differentiated between those with prodromal syndrome and psychotic syndrome diagnoses on the SIPS versus those with no SIPS diagnoses with 89% sensitivity, 58% specificity, and a positive Likelihood Ratio of 2.12,”the researchers wrote. “A Distress Score measuring the distress or impairment associated with endorsed positive symptoms increased the specificity to 68%, while retaining similar sensitivity of 88%. These results suggest that the PQ-B may be used as an effective, efficient self-report screen for prodromal psychosis syndromes when followed by diagnostic interview, in a two-stage evaluation process in help-seeking populations.”
1: Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis Use and Earlier
Onset of Psychosis: A Systematic Meta-analysis. Arch Gen Psychiatry. 2011
Jun;68(6):555-61. Epub 2011 Feb 7. PubMed PMID: 21300939.
2. Loewy RL, Pearson R, Vinogradov S, Bearden CE, and Cannon TD. Psychosis risk screening with the Prodromal Questionnaire — Brief Version (PQ-B). Schizophr Res. 2011 Jun;129(1):42-6. Epub 2011 Apr 20.
WASHINGTON—A VA panel this summer opted not to add the new depression medication esketamine, Spravato, to the department’s formulary in the usual way. This came despite strong support from President Donald Trump and an effort... View Article
VA Panel Puts Limits on Use of Drug PHILADELPHIA—Is esketamine a revolutionary treatment for depression or just another moderately effective adjunctive medication with some potentially serious risks? The VA’s Medical Advisory Panel leaned toward the... View Article